Patents Examined by Jeffrey E. Russel
  • Patent number: 10314886
    Abstract: Meshes for use to control the movement of bodily fluids, such as blood, are described herein. The mesh can be partially or completely biodegradable or non-biodegradable. In one embodiment, the mesh is formed from one or more self-assembling peptides. The peptides can be in the form of fibers, such as nanofibers. The peptides can be assembled prior to formation of the mesh or after the mesh has been formed but before it is applied. Alternatively, the mesh can be prepared from unassembled peptides, which assemble at the time of application. The peptides can assemble upon contact with bodily fluids (e.g., blood) or can be contacted with an ionic solution to initiate assembly.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: June 11, 2019
    Assignee: Arch Biosurgery, inc.
    Inventors: Terrence Norchi, Steven Kates, Rutledge Ellis-Behnke
  • Patent number: 10314889
    Abstract: This disclosure relates to compositions of isolated polypeptides and methods of their use for the treatment and prevention of disease or disease symptoms associated with MARCKS phosphorylation and/or dissociation from the cell membrane, including but not limited to allergic inflammation, asthma, chronic bronchitis, COPD, infection, hyper-reactivity, cystic fibrosis, ulcerative colitis, Crohn's disease, irritable bowel syndrome, rosacea, eczema, psoriasis, acne, arthritis, rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: June 11, 2019
    Assignee: The Regents of the University of California
    Inventors: Reen Wu, Ching-Hsien Chen, Chen-Chen Lee
  • Patent number: 10308701
    Abstract: The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids, e.g., phosphorylation and/or sulfation, to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: June 4, 2019
    Assignee: Purdue Research Foundation
    Inventors: Elizabeth M. Murphy Topp, Hamed Tabatabaei Ghomi, Markus Lill, Shenbaga Moorthy Balakrishnan
  • Patent number: 10307459
    Abstract: Good bioavailability of desmopressin can be obtained with an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary nocturnal enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 4, 2019
    Assignee: FERRING B.V.
    Inventors: Anders Nilsson, Hans Lindner, Jørgen Wittendorff
  • Patent number: 10295537
    Abstract: A biorecognition element for detection of fuel biocontamination. The biorecognition element includes a sequence selected from SEQ. ID No. 10, SEQ. ID No. 13, SEQ. ID No. 22, SEQ. ID No. 27, SEQ. ID No. 31, SEQ. ID No.40, SEQ. ID No.67, SEQ. ID No. 68, SEQ. ID No. 69, SEQ. ID No. 70, SEQ. ID No. 71, and SEQ. ID No.72, an amine-functionalized quantum dot, a C-terminal, three-glycine plus cysteine linker, and a reporter molecule conjugated to the amine-functionalized quantum dot. Biocontaminants are labeled by the biorecognition element and observed via the reporter molecule of the biorecognition element.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: May 21, 2019
    Assignee: The United States of America as represened by the Secretary of the Air Force
    Inventors: Oscar N Ruiz, Oksana Pavlyuk
  • Patent number: 10286033
    Abstract: The invention provides methods and compositions for use of desmopressin in combination with an alpha-adrenergic receptor antagonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 14, 2019
    Assignee: Serenity Pharmaceuticals, LLC
    Inventors: Seymour H. Fein, Linda Cheng, Maria Cheng, Samuel Herschkowitz
  • Patent number: 10280194
    Abstract: Novel synthesized amino acids of glutamine and lysine that are directly PEGylated with small, monodisperse PEGs, and a novel process for creating novel amino acid monomers using PEGylation. These amino acids are readily incorporated into peptides for a range of different applications.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: May 7, 2019
    Assignee: Clemson University
    Inventors: Modi Wetzler, Paris Lamont Hamilton
  • Patent number: 10281473
    Abstract: The application discloses compositions, methods, systems, and apparatuses for rapid sequence analysis of proteins, including location of post-translational modifications and disulfide bonds. Limited digestion of fully denatured antibody occurs in seconds by flowing sample in 8M urea at constant pressure through a micro column reactor containing immobilized aspergillopepsin I, resulting in a product mixture containing 3-10 kDa peptides, which is then fractionated by capillary column chromatography and analyzed by both electron transfer dissociation (ETD) and collision activated dissociation mass spectrometry. This method provides 95% sequence coverage of a mAb and detects numerous post-translational modifications. For disulfide bond location, native mAb is subjected to longer digestion times. Release of disulfide containing peptides from accessible regions of the folded protein occurs with short digestion times.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: May 7, 2019
    Assignee: University of Virginia Patent Foundation
    Inventors: Donald F. Hunt, Weihan Wang, Lichao Zhang
  • Patent number: 10271546
    Abstract: Described is the specific delivery of agrochemicals to plants. More specifically, a targeting agent has at least one binding domain that specifically binds to a binding site on an intact living plant. Such binding domains include a peptide having 4 framework regions and 3 complementary determining regions, or fragment(s) thereof, wherein the binding domains bind or retain a carrier onto a plant. Described are binding domains that specifically bind trichomes, stomata, cuticle, lenticels, thorns, spines, root hairs, or wax layer. Further described are methods for delivering agrochemicals to a plant, for depositing agrochemicals on a plant, and for retaining the agrochemicals on a plant, using targeting agents comprising the binding domains, and to methods for protecting a plant against stress or controlling plant growth. Also, described are methods for manufacturing a specifically targeting agrochemical carrier.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: April 30, 2019
    Assignee: Agrosavfe n.v.
    Inventors: Erik Jongedijk, Peter Verheesen
  • Patent number: 10266567
    Abstract: Isolated peptides are disclosed. The peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-5 and 11-15, with the proviso that the amino acid sequence does not consist of SEQ ID NO: 11, SEQ ID NO: 15 or SEQ ID NO: 1, wherein the peptide is no longer than 50 amino acids. Pharmaceutical compositions comprising same and uses thereof for treatment of diseases associated with serotonin transport and/or ?V?3 activity are also disclosed.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: April 23, 2019
    Assignee: Ariel-University Research and Development Company Ltd.
    Inventors: Albert Pinhasov, Osnat Ashur-Fabian
  • Patent number: 10259859
    Abstract: The present disclosure features signal-regulatory protein ? (SIRP-?) polypeptides and constructs that are useful, e.g., to target a cell (e.g., a cancer cell or a cell of the immune system), to increase phagocytosis of the target cell, to eliminate immune cells such as regulatory T-cells, to kill cancer cells, to treat a disease (e.g., cancer) in a subject, or any combinations thereof. The SIRP-? constructs include a high affinity SIRP-? D1 domain or variant thereof that binds CD47 with higher affinity than a wild-type SIRP-?. The SIRP-? polypeptides or constructs include a SIRP-? D1 variant fused to an Fc domain monomer, a human serum albumin (HSA), an albumin-binding peptide, or a polyethylene glycol (PEG) polymer. Compositions provided herein include (i) a polypeptide including a signal-regulatory protein ? (SIRP-?) D1 variant and (ii) an antibody.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: April 16, 2019
    Assignee: ALX ONCOLOGY INC.
    Inventors: Jaume Pons, Laura Deming, Corey Goodman, Bang Janet Sim, Steven Elliot Kauder, Hong Wan, Tracy Chia-Chien Kuo
  • Patent number: 10260055
    Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of cargo proteins, such as transcription factors, tumor suppressors, developmental regulators, growth factors, metastasis suppressors, pro-apoptotic proteins, nucleases, recombinases, and reprogramming factors into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: April 16, 2019
    Assignees: President and Fellows of Harvard College, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Quan Lu, Qiyu Wang, Stanley N. Cohen
  • Patent number: 10253089
    Abstract: A delivery system that includes a recombinantly synthesized protein polymer with protease cleavage sites such as matrix metalloproteinase responsive sequences engineered within the protein polymer. The system may be used to treat cancer, wounds, or pathological conditions in other tissues that express excess protease relative to healthy tissue.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: April 9, 2019
    Assignee: University of Utah Research Foundation
    Inventors: Hamidreza Ghandehari, Joseph Cappello, Jordan Frandsen, Joshua Gustafson, Khaled Greish, Robert Andrew Price
  • Patent number: 10239914
    Abstract: An improvement of deprotection in solid phase peptide synthesis is disclosed. The method includes the steps of adding the deprotection composition in high concentration and small volume to the mixture of the coupling solution, the growing peptide chain, and any excess activated amino acid from the preceding coupling cycle; and without any draining step between the coupling step of the previous cycle and the addition of the deprotection composition for the successive cycle; and with the coupling solution at a temperature of at least 30° C.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: March 26, 2019
    Assignee: CEM Corporation
    Inventor: Jonathan M. Collins
  • Patent number: 10226508
    Abstract: The present invention provides a pharmaceutical formulation comprising LL-37 or a pharmaceutically-acceptable salt thereof and one or more pharmaceutically-acceptable diluent or carrier system, for use in a method of treatment of a chronic ulcer wound (such as a hard-to-heal venous leg ulcer or a diabetic foot ulcer), which method comprises: (a) topical application of the formulation to the ulcer; followed by (b) application of a dressing, and wherein the application of the formulation provides for a dose of LL-37 at the wound site that is below about 80 ?g of LL-37 applied per cm2 of wound area, and/or below about 26.7 ?g of LL-37 applied per cm2 of wound area, per day of treatment.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: March 12, 2019
    Assignee: Promore Pharma AB
    Inventors: Alvar Grönberg, Christine Dieterich, Margit Mahlapuu
  • Patent number: 10227384
    Abstract: This invention is generally related to small proteins, such as miniature proteins, including avian pancreatic polypeptide (aPP), modified so that the small proteins reach the cytosol. In some embodiments, the modified protein molecules deliver an associated cargo molecule to the cytosol. Other embodiments of the invention relate to modified protein fusion molecules that reach the cytosol.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: March 12, 2019
    Assignee: YALE UNIVERSITY
    Inventors: Alanna S. Schepartz, Jacob S. Applebaum, Jonathan R. LaRochelle
  • Patent number: 10213476
    Abstract: Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds include a modified compstatin peptide or analog thereof, comprising an added N-terminal component that improves (1) the binding affinity of the peptide to C3, C3b or C3c and/or (2) the plasma stability and/or plasma residence time of the peptide, as compared with an unmodified compstatin peptide under equivalent conditions. Methods of improving the C3 binding of compstatin or compstatin analogs are also disclosed, as well as methods of designing compstatin analogs with improved C3 binding.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: February 26, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Daniel Ricklin
  • Patent number: 10206975
    Abstract: The present invention relates to C5 binding polypeptides, comprising a C5 binding motif, BM, which motif consists of an amino acid sequence selected from i) EX2X3X4A X6 X7EID X11LPNL X16X17X18QW X21AFIX25X26LX28D, and ii) an amino acid sequence which has at least 86% identity to the sequence defined in i), wherein the polypeptide binds to C5. The present invention moreover relates to C5 binding polypeptides for use in therapy, such as for use in treatment of a C5 related condition, and to methods of treatment.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 19, 2019
    Assignee: Swedish Orphan Biovitrum AB (PUBL)
    Inventors: Charlotta Berghard, Magnus Berglund, Patrik Strömberg, Malin Lindborg, Elin Gunneriusson, Joachim Feldwisch
  • Patent number: 10206973
    Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c, as chloride salts. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. The chloride salt of TAT-NR2B9c shows improved stability compared with the acetate salt form of prior formulations. Formulations of the chloride salt of TAT-NR2B9c are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: February 19, 2019
    Assignee: NoNO INC.
    Inventor: Jonathan David Garman
  • Patent number: 10206935
    Abstract: This application is directed to cream that treats canine pododermatitis that is caused by a bacterial infection. The cream is composed of a Sulfur mineral powder, a Hydrocortisone cream, a Tolnaftate cream and a triple antibiotic cream. The cream is applied to the affected areas of the dog's paws 2-3 times daily for a period of at least two weeks.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: February 19, 2019
    Inventor: Griselle J Garcia